Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab plus Oxaliplatin-based Chemotherapy for Colorectal Cancer Liver Metastases
NCT01763450Phase 2
Key facts
- Status
- Unknown
- Start
- Sep 2012
- Primary completion
- May 2013
- Countries
- 1
- Sponsor
- Liaoning Medical Center
- Drugs
- bevacizumab
- Conditions
- Colorectal cancer with liver metastases (CRLM)
01
Overview
Phase 2, open-label trial of bevacizumab in Colorectal cancer with liver metastases (CRLM), sponsored by Liaoning Medical Center. Status: unknown.
02
Design
- Study design
- Non-randomizedOpen-label
03
Who it enrols
Patients aged 18-80 with unresectable liver metastases from colorectal adenocarcinoma, ECOG 0-1, and no prior chemotherapy within 6 months.
04
Registry description
A multi-center, non-random, open study ,to observe efficacy and safety of bevacizumab plus Oxaliplatin based multidrug chemotherapy as conversion therapy for patients with previously untreated unresectable liver metastases from colorectal cancer.
Beyond the preview
Go deeper on NCT01763450.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01763450.